Ronald M. Krauss
Research Subjects
Research Interests
Ronald M. Krauss has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Patricia J. Blanche
From the Department of Genome Sciences (M.R., P.J.B., R.M.K.), Lawrence Berkeley National Laboratory, University of California, Berkeley; the Department of Clinical Medicine and Emerging Diseases (M.R., C.M.B.), University of Palermo, Italy; the Gladstone Institute of Cardiovascular Disease (J.M.T.), University of California, San Francisco; and the Department of Internal Medicine (K.B.), University Hospital Bruderholz, Switzerland
3 shared publicationsPaul T Williams
From the Children's Hospital Oakland, Oakland, CA, and the Donner Laboratory, Ernest Orlando Lawrence Berkeley Laboratory, University of California, Berkeley
3 shared publicationsDarlene M Dreon
Children's Hospital Oakland, Oakland, CA, and the Donner Laboratory, Ernest Orlando Lawrence Berkeley Laboratory, University of California, Berkeley, CA 94720, USA
2 shared publicationsHarriett A Fernstrom
From the Children's Hospital Oakland, Oakland, CA, and the Donner Laboratory, Ernest Orlando Lawrence Berkeley Laboratory, University of California, Berkeley
2 shared publicationsJohn M. Taylor
From the Department of Genome Sciences (M.R., P.J.B., R.M.K.), Lawrence Berkeley National Laboratory, University of California, Berkeley; the Department of Clinical Medicine and Emerging Diseases (M.R., C.M.B.), University of Palermo, Italy; the Gladstone Institute of Cardiovascular Disease (J.M.T.), University of California, San Francisco; and the Department of Internal Medicine (K.B.), University Hospital Bruderholz, Switzerland
2 shared publications- Manfredi Rizzo
RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates
2 shared publications
Latest Publications
- 1 July 2004
- Published by Elsevier in Medical Clinics of North America
- Vol. 88 (4) , 897-909
Dyslipidemia in type 2 diabetes
- 1 July 2004
- Published by Elsevier in Medical Clinics of North America
- Vol. 88 (4) , 897-909
Dyslipidemia in type 2 diabetes
- 1 June 2004
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (6) , 1496-1504
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Insulin resistance and type 2 diabetes are associated with a clustering of interrelated plasma lipid and lipoprotein abnormalities, which include reduced HDL cholesterol, a predominance of small dense LDL particles, and elevated triglyceride levels. Each of these dyslipidemic features is associated with an increased risk of cardiovascular disease. Increased hepatic secretion of large triglyceride-rich VLDL and impaired clearance of VLDL appears to be of central importance in the pathophysiology of this dyslipidemia. Small dense LDL particles arise from the intravascular processing of specific larger VLDL precursors. Typically, reduced plasma HDL levels in type 2 diabetes are manifest as reductions in the HDL2b subspecies and relative or absolute increases in smaller denser HDL3b and HDL3c. Although behavioral interventions such as diet and exercise can improve diabetic dyslipidemia, for most patients, pharmacological therapy is needed to reach treatment goals. There are several classes of medications that can be used to treat lipid and lipoprotein abnormalities associated with insulin resistance and type 2 diabetes, including statins, fibrates, niacin, and thiazolidinediones. Clinical trials have shown significant improvement in coronary artery disease after diabetic dyslipidemia treatment.
- 1 June 2004
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (6) , 1496-1504
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Insulin resistance and type 2 diabetes are associated with a clustering of interrelated plasma lipid and lipoprotein abnormalities, which include reduced HDL cholesterol, a predominance of small dense LDL particles, and elevated triglyceride levels. Each of these dyslipidemic features is associated with an increased risk of cardiovascular disease. Increased hepatic secretion of large triglyceride-rich VLDL and impaired clearance of VLDL appears to be of central importance in the pathophysiology of this dyslipidemia. Small dense LDL particles arise from the intravascular processing of specific larger VLDL precursors. Typically, reduced plasma HDL levels in type 2 diabetes are manifest as reductions in the HDL2b subspecies and relative or absolute increases in smaller denser HDL3b and HDL3c. Although behavioral interventions such as diet and exercise can improve diabetic dyslipidemia, for most patients, pharmacological therapy is needed to reach treatment goals. There are several classes of medications that can be used to treat lipid and lipoprotein abnormalities associated with insulin resistance and type 2 diabetes, including statins, fibrates, niacin, and thiazolidinediones. Clinical trials have shown significant improvement in coronary artery disease after diabetic dyslipidemia treatment.
- 1 June 2004
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 33 (2) , 405-415
Metabolic abnormalities: triglyceride and low-density lipoprotein
- 1 June 2004
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 33 (2) , 405-415
Metabolic abnormalities: triglyceride and low-density lipoprotein
- 1 May 2004
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 113 (9) , 1253-1255
Hold the antioxidants and improve plasma lipids?
Intrahepatic proteolysis is a major determinant of secretion of ApoB-containing lipoproteins into plasma. Stimulation of post-ER presecretory proteolysis (PERPP) of ApoB by n-3 polyunsaturated fatty acids has been found to result in reduced secretion of VLDL particles by hepatocytes. A new study has shown that this stimulation is promoted by pro-oxidant conditions that result in increased hepatic lipid hydroperoxide content. Conversely, PERPP is suppressed by antioxidants and by saturated fatty acids, which are not susceptible to lipid peroxidation. Hence reduction of oxidative stress may have the unexpected side effect of increasing plasma lipid levels.
- 1 May 2004
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 113 (9) , 1253-1255
Hold the antioxidants and improve plasma lipids?
Intrahepatic proteolysis is a major determinant of secretion of ApoB-containing lipoproteins into plasma. Stimulation of post-ER presecretory proteolysis (PERPP) of ApoB by n-3 polyunsaturated fatty acids has been found to result in reduced secretion of VLDL particles by hepatocytes. A new study has shown that this stimulation is promoted by pro-oxidant conditions that result in increased hepatic lipid hydroperoxide content. Conversely, PERPP is suppressed by antioxidants and by saturated fatty acids, which are not susceptible to lipid peroxidation. Hence reduction of oxidative stress may have the unexpected side effect of increasing plasma lipid levels.
- 1 January 2004
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (1) , 141-146
Effects on Lipoprotein Subclasses of Combined Expression of Human Hepatic Lipase and Human apoB in Transgenic Rabbits
Objective— The effects of combined expression of human hepatic lipase (HL) and human apolipoprotein B (apoB) on low-density lipoprotein (LDL) subclasses were examined in rabbits, a species naturally deficient in HL activity. Methods and Results— In apoB-transgenic rabbit plasma, >80% of the protein was found in the 1.006- to 1.050-g/mL fraction. Gradient gel electrophoresis (GGE) of this fraction revealed two distinct species, designated large and small LDL. A denser fraction (d=1.050 to 1.063 g/mL) contained small LDL as well as another discrete LDL subspecies, designated very small LDL. Expression of HL resulted in reductions in protein concentrations in the 1.006- to 1.050-g/mL density-gradient subfractions containing large (6.5±4.1 versus 32.6±12.0 mg/dL, P P P Conclusion— These findings support a direct role for HL in regulating total plasma LDL concentrations as well as in the production of smaller, denser LDL from larger, more buoyant precursors.
- 1 January 2004
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (1) , 141-146
Effects on Lipoprotein Subclasses of Combined Expression of Human Hepatic Lipase and Human apoB in Transgenic Rabbits
Objective— The effects of combined expression of human hepatic lipase (HL) and human apolipoprotein B (apoB) on low-density lipoprotein (LDL) subclasses were examined in rabbits, a species naturally deficient in HL activity. Methods and Results— In apoB-transgenic rabbit plasma, >80% of the protein was found in the 1.006- to 1.050-g/mL fraction. Gradient gel electrophoresis (GGE) of this fraction revealed two distinct species, designated large and small LDL. A denser fraction (d=1.050 to 1.063 g/mL) contained small LDL as well as another discrete LDL subspecies, designated very small LDL. Expression of HL resulted in reductions in protein concentrations in the 1.006- to 1.050-g/mL density-gradient subfractions containing large (6.5±4.1 versus 32.6±12.0 mg/dL, P P P Conclusion— These findings support a direct role for HL in regulating total plasma LDL concentrations as well as in the production of smaller, denser LDL from larger, more buoyant precursors.
- 1 February 2003
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (2) , 314-321
Smallest LDL Particles Are Most Strongly Related to Coronary Disease Progression in Men
Objective— LDLs include particle subclasses that have different mobilities on polyacrylamide gradient gels: LDL-I (27.2 to 28.5 nm), LDL-IIa (26.5 to 27.2 nm), LDL-IIb (25.6 to 26.5 nm), LDL-IIIa (24.7 to 25.6 nm), LDL-IIIb (24.2 to 24.7 nm), LDL-IVa (23.3 to 24.2 nm), and LDL-IVb (22.0 to 23.3 nm in diameter). We hypothesized that the association between smaller LDL particles and coronary artery disease (CAD) risk might involve specific LDL subclasses. Methods and Results— Average 4-year onstudy lipoprotein measurements were compared with annualized rates of stenosis change from baseline to 4 years in 117 men with CAD. The percentages of total LDL and HDL occurring within individual subclasses were measured by gradient gel electrophoresis. Annual rate of stenosis change was related concordantly to onstudy averages of total cholesterol ( P =0.04), triglycerides ( P =0.05), VLDL mass ( P =0.03), total/HDL cholesterol ratio ( P =0.04), LDL-IVb ( P =0.01), and HDL 3a ( P =0.02) and inversely to HDL 2 -mass ( P =0.02) and HDL 2b ( P =0.03). The average annual rate in stenosis change was 6-fold more rapid in the fourth quartile of LDL-IVb (≥5.2%) than in the first quartile (P =0.03). Stepwise multiple regression analysis showed that LDL-IVb was the single best predictor of stenosis change. Conclusions— LDL-IVb was the single best lipoprotein predictor of increased stenosis, an unexpected result, given that LDL-IVb represents only a minor fraction of total LDL.
- 1 February 2003
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (2) , 314-321
Smallest LDL Particles Are Most Strongly Related to Coronary Disease Progression in Men
Objective— LDLs include particle subclasses that have different mobilities on polyacrylamide gradient gels: LDL-I (27.2 to 28.5 nm), LDL-IIa (26.5 to 27.2 nm), LDL-IIb (25.6 to 26.5 nm), LDL-IIIa (24.7 to 25.6 nm), LDL-IIIb (24.2 to 24.7 nm), LDL-IVa (23.3 to 24.2 nm), and LDL-IVb (22.0 to 23.3 nm in diameter). We hypothesized that the association between smaller LDL particles and coronary artery disease (CAD) risk might involve specific LDL subclasses. Methods and Results— Average 4-year onstudy lipoprotein measurements were compared with annualized rates of stenosis change from baseline to 4 years in 117 men with CAD. The percentages of total LDL and HDL occurring within individual subclasses were measured by gradient gel electrophoresis. Annual rate of stenosis change was related concordantly to onstudy averages of total cholesterol ( P =0.04), triglycerides ( P =0.05), VLDL mass ( P =0.03), total/HDL cholesterol ratio ( P =0.04), LDL-IVb ( P =0.01), and HDL 3a ( P =0.02) and inversely to HDL 2 -mass ( P =0.02) and HDL 2b ( P =0.03). The average annual rate in stenosis change was 6-fold more rapid in the fourth quartile of LDL-IVb (≥5.2%) than in the first quartile (P =0.03). Stepwise multiple regression analysis showed that LDL-IVb was the single best predictor of stenosis change. Conclusions— LDL-IVb was the single best lipoprotein predictor of increased stenosis, an unexpected result, given that LDL-IVb represents only a minor fraction of total LDL.
- Open Access
- 1 September 2002
- Published by Elsevier in Journal of Lipid Research
- Vol. 43 (9) , 1363-1379
Metabolic origins and clinical significance of LDL heterogeneity
- 1 September 2002
- Published by Elsevier in Journal of Lipid Research
- Vol. 43 (9) , 1363-1379
Open AccessMetabolic origins and clinical significance of LDL heterogeneity
- 1 July 2001
- Published by Annual Reviews in Annual Review of Nutrition
- Vol. 21 (1) , 283-295
DIETARY AND GENETIC EFFECTS ON LOW-DENSITY LIPOPROTEIN HETEROGENEITY
▪ Abstract We have tested whether differences in distribution and dietary responsiveness of low-density lipoprotein (LDL) subclasses contribute to the variability in the magnitude of LDL-cholesterol reduction induced by diets low in total and saturated fat and high in carbohydrate. Our studies have focused on a common, genetically influenced metabolic profile, characterized by a predominance of small, dense LDL particles (subclass pattern B), that is associated with a two- to threefold increase in risk for coronary artery disease. We have found that healthy normolipidemic individuals with this trait show a greater reduction in LDL cholesterol and particle number in response to low-fat, high-carbohydrate diets than do unaffected individuals (subclass pattern A). Moreover, such diets result in reduced LDL particle size, with induction of pattern B in a substantial proportion of pattern A men. Recent studies have indicated that this response is under genetic influence. Future identification of the specific genes involved may lead to improved targeting of dietary therapies aimed at reducing cardiovascular disease risk.
- 1 July 2001
- Published by Annual Reviews in Annual Review of Nutrition
- Vol. 21 (1) , 283-295
DIETARY AND GENETIC EFFECTS ON LOW-DENSITY LIPOPROTEIN HETEROGENEITY
▪ Abstract We have tested whether differences in distribution and dietary responsiveness of low-density lipoprotein (LDL) subclasses contribute to the variability in the magnitude of LDL-cholesterol reduction induced by diets low in total and saturated fat and high in carbohydrate. Our studies have focused on a common, genetically influenced metabolic profile, characterized by a predominance of small, dense LDL particles (subclass pattern B), that is associated with a two- to threefold increase in risk for coronary artery disease. We have found that healthy normolipidemic individuals with this trait show a greater reduction in LDL cholesterol and particle number in response to low-fat, high-carbohydrate diets than do unaffected individuals (subclass pattern A). Moreover, such diets result in reduced LDL particle size, with induction of pattern B in a substantial proportion of pattern A men. Recent studies have indicated that this response is under genetic influence. Future identification of the specific genes involved may lead to improved targeting of dietary therapies aimed at reducing cardiovascular disease risk.
- Open Access
- 1 June 2000
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 71 (6) , 1611-1616
Reduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns
Background: A genetically influenced atherogenic lipoprotein phenotype characterized by a predominance of small, dense LDL particles (subclass pattern B) can be induced by low-fat diets in healthy subjects with large LDL particles (pattern A). Objective: The aim of this study was to test whether genetic predisposition to subclass pattern B contributes to susceptibility to induction of this trait by a low-fat diet. Design: The prevalence of pattern B in children is relatively low compared with that in older individuals, but genetic susceptibility to this trait in offspring can be inferred by its presence in their parents. Plasma lipoproteins were analyzed 10 d after a change from a usual diet to a very-low-fat (10% fat), high-carbohydrate diet in offspring (mean age: 14 y; range: 7–28 y) of 22 families according to parental LDL-subclass patterns when consuming a low-fat diet: A×A mating (9 families with 19 children), A×B mating (5 families with 10 children), and B×B mating (8 families with 21 children). Results: The very-low-fat, high-carbohydrate diet produced significantly greater decreases in LDL particle size in offspring of B×B parents (x̄ ± SE: −0.55 ± 0.16 nm) and A×B parents (−0.48 ± 0.19 nm) than in offspring of A×A parents (0.14 ± 0.20 nm). The number of children expressing pattern B with the 10%-fat diet and the proportion of children converting from pattern A to pattern B was significantly greater in offspring of B×B parents than in those with 1 or 2 pattern A parents. Conclusion: A very-low-fat, high-carbohydrate diet can induce expression of LDL-subclass pattern B in genetically predisposed children with low expression of the trait while consuming their usual diets.
- 1 June 2000
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 71 (6) , 1611-1616
Open AccessReduced LDL particle size in children consuming a very-low-fat diet is related to parental LDL-subclass patterns
Background: A genetically influenced atherogenic lipoprotein phenotype characterized by a predominance of small, dense LDL particles (subclass pattern B) can be induced by low-fat diets in healthy subjects with large LDL particles (pattern A). Objective: The aim of this study was to test whether genetic predisposition to subclass pattern B contributes to susceptibility to induction of this trait by a low-fat diet. Design: The prevalence of pattern B in children is relatively low compared with that in older individuals, but genetic susceptibility to this trait in offspring can be inferred by its presence in their parents. Plasma lipoproteins were analyzed 10 d after a change from a usual diet to a very-low-fat (10% fat), high-carbohydrate diet in offspring (mean age: 14 y; range: 7–28 y) of 22 families according to parental LDL-subclass patterns when consuming a low-fat diet: A×A mating (9 families with 19 children), A×B mating (5 families with 10 children), and B×B mating (8 families with 21 children). Results: The very-low-fat, high-carbohydrate diet produced significantly greater decreases in LDL particle size in offspring of B×B parents (x̄ ± SE: −0.55 ± 0.16 nm) and A×B parents (−0.48 ± 0.19 nm) than in offspring of A×A parents (0.14 ± 0.20 nm). The number of children expressing pattern B with the 10%-fat diet and the proportion of children converting from pattern A to pattern B was significantly greater in offspring of B×B parents than in those with 1 or 2 pattern A parents. Conclusion: A very-low-fat, high-carbohydrate diet can induce expression of LDL-subclass pattern B in genetically predisposed children with low expression of the trait while consuming their usual diets.
- Open Access
- 1 March 2000
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 71 (3) , 668-669
Genetic recipes for heart-healthy diets
Given the major impact of nutrients such as saturated fat and cholesterol on plasma lipoproteins, it is reasonable to suppose that interindividual variations in genes affecting lipoprotein metabolism and controlling intestinal nutrient absorption contribute to the large differences in lipoprotein response to dietary change that have been shown to exist among individuals (1, 2). Most specific gene variants found to date, however, have been studied primarily in relation to plasma concentrations of lipids and lipoproteins (“level” genes) rather than in relation to changes caused by diet or other sources of variation (“variability” genes) (3).
- 1 March 2000
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 71 (3) , 668-669
Open AccessGenetic recipes for heart-healthy diets
Given the major impact of nutrients such as saturated fat and cholesterol on plasma lipoproteins, it is reasonable to suppose that interindividual variations in genes affecting lipoprotein metabolism and controlling intestinal nutrient absorption contribute to the large differences in lipoprotein response to dietary change that have been shown to exist among individuals (1, 2). Most specific gene variants found to date, however, have been studied primarily in relation to plasma concentrations of lipids and lipoproteins (“level” genes) rather than in relation to changes caused by diet or other sources of variation (“variability” genes) (3).